Covid-19 in recipients of living donor liver transplantation: a worse or an equivalent outcome?
Journal
QJM : monthly journal of the Association of Physicians
ISSN: 1460-2393
Titre abrégé: QJM
Pays: England
ID NLM: 9438285
Informations de publication
Date de publication:
21 Feb 2022
21 Feb 2022
Historique:
received:
08
10
2021
revised:
17
12
2021
pubmed:
29
12
2021
medline:
24
2
2022
entrez:
28
12
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 (Covid-19) pandemic is representing a massive burden to the community with the new virus. There is few data regarding Covid-19 in liver transplant patients. Concerns were raised regarding the course of the disease in transplanted patients due to immunosuppression and risk of hepatic injuries. To describe the outcomes of Covid-19 infection in recipients of living-donor liver transplantation (LDLT). Retrospective analysis of 41 recipients of LDLT diagnosed with Covid-19 by real-time PCR or CT chest criteria of Covid-19 between April 2020 and April 2021. This Cohort was derived from Ain Shams Center for Organ Transplantation database, Ain Shams Specialized Hospital, Cairo, Egypt, which is considered one of the largest centers of LDLT in the Middle East. Patients were classified to mild, moderate, severe and critics according to clinical classification released by the National Health Commission of China. A total of 41 patients and 2 patients with reinfection were included in this cohort with mean age 54 years with 74% male and 26% female. The body mass index ranged from 19.3 to 37. About 30% were described as a mild case, 46.5% were moderate, 14% were severe and 9% were critical cases. Two cases developed infection twice. Total of 20 patients (46.5%) were managed in home isolation setting, 17 patients (39.5%) needed admission to ward, 4 patients (9%) in intermediate care unit and 2 patients (4%) admitted to intensive care unit. About 60% of cases were on room air, only 3 patients needed invasive methods, 2 patients needed face mask and 1 case needed invasive CPAP. In total, 41 patients recovered (95%) and 2 patients (5%) died; 1 was Covid related and the other one was non-Covid related. Female gender, higher BMI and hypertension were associated with severe course of the disease. In the setting of LDLT, the possibilities of catching Covid-19 infection are high due to chronic immunosuppression use. Yet, the outcome of infection in term of morbidity and the needs for hospital admission or intensive care is generally matched to general population.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (Covid-19) pandemic is representing a massive burden to the community with the new virus. There is few data regarding Covid-19 in liver transplant patients. Concerns were raised regarding the course of the disease in transplanted patients due to immunosuppression and risk of hepatic injuries.
AIM
OBJECTIVE
To describe the outcomes of Covid-19 infection in recipients of living-donor liver transplantation (LDLT).
METHODS
METHODS
Retrospective analysis of 41 recipients of LDLT diagnosed with Covid-19 by real-time PCR or CT chest criteria of Covid-19 between April 2020 and April 2021. This Cohort was derived from Ain Shams Center for Organ Transplantation database, Ain Shams Specialized Hospital, Cairo, Egypt, which is considered one of the largest centers of LDLT in the Middle East. Patients were classified to mild, moderate, severe and critics according to clinical classification released by the National Health Commission of China.
RESULTS
RESULTS
A total of 41 patients and 2 patients with reinfection were included in this cohort with mean age 54 years with 74% male and 26% female. The body mass index ranged from 19.3 to 37. About 30% were described as a mild case, 46.5% were moderate, 14% were severe and 9% were critical cases. Two cases developed infection twice. Total of 20 patients (46.5%) were managed in home isolation setting, 17 patients (39.5%) needed admission to ward, 4 patients (9%) in intermediate care unit and 2 patients (4%) admitted to intensive care unit. About 60% of cases were on room air, only 3 patients needed invasive methods, 2 patients needed face mask and 1 case needed invasive CPAP. In total, 41 patients recovered (95%) and 2 patients (5%) died; 1 was Covid related and the other one was non-Covid related. Female gender, higher BMI and hypertension were associated with severe course of the disease.
CONCLUSION
CONCLUSIONS
In the setting of LDLT, the possibilities of catching Covid-19 infection are high due to chronic immunosuppression use. Yet, the outcome of infection in term of morbidity and the needs for hospital admission or intensive care is generally matched to general population.
Identifiants
pubmed: 34963013
pii: 6486417
doi: 10.1093/qjmed/hcab329
pmc: PMC9383128
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-76Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):384-389
pubmed: 34305351
Liver Int. 2020 Aug;40(8):1972-1976
pubmed: 32471013
J Hepatol. 2021 Jan;74(1):148-155
pubmed: 32750442
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):643-644
pubmed: 32339474
Am J Transplant. 2020 Jul;20(7):1809-1818
pubmed: 32282982
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
J Clin Transl Hepatol. 2020 Dec 28;8(4):467-473
pubmed: 33447532
Blood. 2013 Jun 27;121(26):5154-7
pubmed: 23678006
Gastroenterology. 2020 Sep;159(3):1176-1178.e2
pubmed: 32442561
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Kidney Int. 2020 Jun;97(6):1083-1088
pubmed: 32354634
Gastroenterology. 2021 Mar;160(4):1151-1163.e3
pubmed: 33307029
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533
pubmed: 32278366
Liver Transpl. 2020 Dec;26(12):1665-1666
pubmed: 33021025
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066